Investor Relations

Corporate Profile

We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc.

Data Provided by Refinitiv. Minimum 15 minutes delayed.